@article{3050863,
    title = "Salvage treatment with paclitaxel and gemcitabine for patients with
non-small-cell lung cancer after cisplatin- or docetaxel-based
chemotherapy: A multicenter phase II study",
    author = "Androulakis, N and Kouroussis, C and Kakolyris, S and Tzannes, S and and Papadakis, E and Papadimitriou, C and Geroyianni, A and Georgopoulou, T and and Dimopoulou, I and Souglakos, J and Kotsakis, A and Vardakis, N and and Hatzidaki, D and Georgoulias, V",
    journal = "Annals of Oncology",
    year = "1998",
    volume = "9",
    number = "10",
    pages = "1127-1130",
    publisher = "KLUWER ACADEMIC PUBL",
    issn = "0923-7534, 1569-8041",
    doi = "10.1023/A:1008497322508",
    keywords = "gemcitabine; non-small-cell lung cancer; paclitaxel; phase II trial",
    abstract = "Background. To evaluate the tolerance and efficacy of the combination of
paclitaxel and gemcitabine as salvage treatment in patients with
advanced non-small-cell lung cancer (NSCLC). Patients and methods.
Forty-nine patients with measurable NSCLC (PS 0-1: 80%; stage IV: 84%)
who progressed or failed first-line chemotherapy were enrolled. Prior
chemotherapy was cisplatin-based with (n = 20) or without (n = 22)
docetaxel and docetaxel-vinorelbine (n = 7).
Patients received gemcitabine (900 mg/m(2) i.v.; days 1 and 8) and
paclitaxel (175 mg/m(2); day 8) every three weeks; G-CSF (150 mu
g/m(2)/day s.c.; days 9-15) was given prophylactically to all patients.
Results: One (2%) complete and eight (16%) partial responses were
achieved (overall response 18%; 95% CI: 4%-24%); 14 patients (29%)
had stable disease and 26 (53%) progressive disease. Six responses were
observed in 17 patients who responded to first-line chemotherapy. The
median duration of response was seven months, the median TTP eight
months and the median survival 11 months. The one-year survival rate was
37%. Grade 3-4 neutropenia occured in six (12%) patients, grade 2-3
neurotoxicity in 16 (32%) and grade 2-3 asthenia in 25 (51%). Other
toxicities were mild.
Conclusions. The paclitaxel-gemcitabine combination is a well-tolerated
and relatively active salvage regimen in patients with NSCLC and it
merits further investigation."
}